HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Sorafenib Tosylate
4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate · CL050 · Sorafenib &Sorafeni tosylate · SORAFENIB TOSYLATE · Sorafinib mesylate · Sorafenib (Nexavar) · Sorafenib TsOH salt · Sorafenib 475207-59-1
Identifikatoren & physikalische Daten
| CAS No. | 475207-59-1 |
|---|---|
| Summenformel | C28H24ClF3N4O6S |
| Durchschnittliche Molmasse | 637 g/mol |
| Monoisotopische Masse | 636,10571783 g/mol |
| SMILES | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1 |
| InChIKey | IVDHYUQIDRJSTI-UHFFFAOYSA-N |
| PubChem CID | 406563 |
| ChEMBL | CHEMBL1200485 |
| ChEBI | CHEBI:50928 |
| EC No. | 641-758-8 |
| DTXSID | DTXSID9047839 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 155 |
|---|---|
| H-Brücken-Donoren | 4 |
| H-Brücken-Akzeptoren | 10 |
| Frei drehbare Bindungen | 6 |
| Schwere Atome | 43 |
| Formalladung | 0 |
| Komplexität | 853 |
| Human Drugs | Breast FeedingLactationAntineoplastic AgentsEnzyme InhibitorsProtein Kinase InhibitorsSignal Transduction InhibitorsTyrosine Kinase InhibitorsFDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| Schmelzpunkt | 229-232°C |
| Lagerbedingungen | 2-8°C(protect from light) |
| Löslichkeit | Soluble in DMSO (up to 200 mg/ml) or in Ethanol (up to 3 mg/ml). |
| Aggregatzustand | solid |
| Farbe | Off-white |
| Stabilität | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
| InChIKey | IVDHYUQIDRJSTI-UHFFFAOYSA-N |
| SMILES | S(C1C=CC(C)=CC=1)(O)(=O)=O.O(C1C=CC(NC(=O)NC2C=CC(Cl)=C(C(F)(F)F)C=2)=CC=1)C1=CC=NC(C(=O)NC)=C1 |
| CAS Datenbank | 475207-59-1(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH302 (31%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P264, P270, P271, P273, P280, P301+P317, P304+P340, P317, P318, P319, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (31%) |
| Treatment | There is no specific treatment for NEXAVAR (Sorafenib ) overdose. (L1712) |
| Gesundheitliche Auswirkungen | Hand-foot skin reaction and rash represent the most common adverse reactionsmay increase the risk of bleeding (L1712) |
| Expositionspfade | The mean relative bioavailability is 38-49% for the tablet form, when compared to an oral solution. Sorafenib reached peak plasma levels in 3 hours following oral administration. With a high-fat meal, bioavailability is reduced by 29% compared to administration in the fasted state. |
| Toxizitätsübersicht | Sorafenib interacts with multiple intracellular (CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß). Several of these kinases are thought to be involved in angiogenesis, thus sorafenib reduces blood flow to the tumor. Sorafenib is unique in targeting the Raf/Mek/Erk pathway. By inhibiting these kinases, genetic transcription involving cell proliferation and angiogenesis is inhibited. |
| Signs and Symptoms | The highest dose of sorafenib studied clinically is 800 mg twice daily. The adverse reactions observed at this dose were primarily diarrhea and dermatologic events. No information is available on symptoms of acute overdose in animals because of the saturation of absorption in oral acute toxicity studies conducted in animals. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Sorafenib tosylatevMost-DILI-concern8Warnings & precautionsDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Wassergefährdungsklasse (WGK) | WGK 3 |
| Zollcode | 29159000 |
| R-Sätze (R) | 36/37/38 |
| Sicherheitshinweise (S) | 28-26 |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Aquatic Acute 1Aquatic Chronic 1Lact.Repr. 1BSTOT RE 1 |
Anwendungen & Verwendung
Verwenden
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively.